RAP1A and AL amyloidosis: Interestingly, bisphosphonates, which are in clinical practice as inhibitors of bone resorption due to osteoporosis, are potent inhibitors of geranylgeranyl biosynthesis, and thus Rap1, and have proven effective in the therapy of multiple myeloma and breast carcinoma (52–54).